CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation  

作　　者：Qianwen Xu Hui Xu Lei Xue Min Wang Guiwang Pan Xuhan Zhang Kaidi Song Wen Yao Xiang Wan Juan Tong Huilan Liu Hanying Xu Xin Liu Xiaoyu Zhu Zimin Sun Lin Yang Xingbing Wang 

机构地区：[1]Department of Hematology,Anhui Provincial Hospital,Anhui Medical University,Hefei,Anhui 230031,China [2]Department of Hematology,The First Affiliated Hospital of USCT,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui 230001,China [3]PersonGen-Anke Cellular Therapeutics Co.,Ltd.,Hefei,Anhui 230001,China

出　　处：《Chinese Medical Journal》2022年第1期98-100,共3页中华医学杂志（英文版）

基　　金：The work was supported by grants from the Science and Technology Planning Project of Anhui Province,China(No.1604a0802071);the Major Science and Technology Projects of Anhui Province,China(No.18030801126)。

摘　　要：To the Editor:Umbilical cord blood transplant(UCBT)serves as an alternative option for treating patients with B cell acute lymphoblastic leukemia(ALL),in the absence of a compatible donor.However,disease recurrence presents a difficult challenge.Chimeric antigen receptor(CAR)-T cell therapy is a promising approach for treating patients with relapsed/refractory ALL.Among the intensive investigations of infusion of CAR-T cells after transplant,few focus on patients who were administered CAR-T therapy after they relapsed subsequently to UCBT.Here,we report the response rate,toxicity,and survival of CD19 CAR-T cells administered to 10 children and young adults with relapsed acute B lymphoblastic leukemia(B-ALL)after UCBT.Between April 2018 and September 2019,11 patients with relapsed B-ALL after UCBT were enrolled,including three females and eight males,the median age was 10 years(range 7-22 years)and median weight was 35.0 kg(range 21.0-72.0 kg).Patient 10 was excluded because of unsuccessful cell culture.

关 键 词：PATIENTS RELAPSE LYMPHOBLASTIC 

分 类 号：R733.71[医药卫生—肿瘤]